Targeting C9orf72 in people with ALS
-
Published:2024-09
Issue:9
Volume:23
Page:850-852
-
ISSN:1474-4422
-
Container-title:The Lancet Neurology
-
language:en
-
Short-container-title:The Lancet Neurology
Reference6 articles.
1. Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosis;Ruf;Brain Commun,2023
2. Amyotrophic lateral sclerosis;Feldman;Lancet,2022
3. Emerging insights into the complex genetics and pathophysiology of ALS;Goutman;Lancet Neurol,2022
4. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study;van den Berg;Lancet Neurol,2024
5. Trial of antisense oligonucleotide tofersen for SOD1 ALS;Miller;N Engl J Med,2022